NASDAQ:CMPX Compass Therapeutics Q3 2025 Earnings Results & Report $0.83 -0.01 (-0.93%) Closing price 04:00 PM EasternExtended Trading$0.81 -0.02 (-2.79%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Compass Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$0.08 versus the -$0.14 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 5, 2025TimeBefore Market OpensConference Call4:00 PM ET Compass Therapeutics EPS ResultsActual EPS-$0.08Consensus EPS -$0.14Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCompass Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Compass Therapeutics Q3 2025 Earnings FAQ Did Compass Therapeutics beat earnings estimates for Q3 2025? Compass Therapeutics (NASDAQ:CMPX) reported earnings of -$0.08 per share for Q3 2025, beating the consensus estimate of -$0.14. The report was announced on Wednesday, November 5, 2025. Compass Therapeutics Earnings HeadlinesCompass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 11 at 9:42 AM | marketscreener.comMMacro and Geopolitical Risks Threaten Compass Therapeutics’ Costs, Liquidity, and Clinical OperationsNovember 10 at 1:11 AM | tipranks.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 11 at 1:00 AM | Traders Agency (Ad)Compass Therapeutics Advances CTX-471 Cancer Study as Investors Await Early DataNovember 9 at 11:30 AM | tipranks.comCompass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate UpdateNovember 9 at 8:00 AM | globenewswire.comCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual MeetingNovember 6, 2026 | globenewswire.comSee More Compass Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email. Email Address About Compass TherapeuticsCompass Therapeutics (NASDAQ:CMPX) is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors. Its candidates remain under clinical investigation and are not approved medicines. Compass Therapeutics is based in Boston, Massachusetts, and focuses on research and development rather than marketing commercial products. The company’s work is primarily directed toward developing treatments for cancer.View Compass Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
